STOCK TITAN

Theseus Pharmaceuticals, Inc. - THRX STOCK NEWS

Welcome to our dedicated page for Theseus Pharmaceuticals news (Ticker: THRX), a resource for investors and traders seeking the latest updates and insights on Theseus Pharmaceuticals stock.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing transformative targeted therapies. The company is at the forefront of outsmarting cancer resistance, focusing on pan-variant tyrosine kinase inhibitors (TKIs) that target all classes of cancer-causing and resistance mutations, thereby addressing the challenge of treatment resistance.

Core Business: Theseus is pioneering the development of best-in-class, pan-variant kinase inhibitors. Its lead candidate, THE-349, is a fourth-generation epidermal growth factor receptor (EGFR) inhibitor designed to counteract C797X-mediated resistance in non-small cell lung cancer (NSCLC) patients previously treated with osimertinib. The company is also working on a pan-variant BCR-ABL inhibitor for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), and a next-generation, highly selective, pan-variant KIT inhibitor for early-line gastrointestinal stromal tumors (GIST).

Recent Achievements: The company recently made significant progress in its pipeline, despite discontinuing its THE-630 program for GIST due to dose-limiting toxicities observed in clinical trials. However, Theseus is exploring the potential of low-dose THE-630 for KIT-associated mast cell-driven diseases. The company successfully raised $234.2 million in cash and equivalents by June 30, 2023, to fund operations through 2026.

Strategic Developments: In December 2023, Theseus entered into a merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Theseus for a price per share ranging from $3.90 to $4.05 in cash, along with contingent value rights (CVRs). This move aims to maximize shareholder value and includes strategic options such as asset sales, mergers, or other actions.

Partnerships and Products: The company's robust pipeline includes partnerships and potential internal developments targeting various cancer mutations. Theseus is set to nominate development candidates for its BCR-ABL and KIT programs in early 2024 and anticipates filing an Investigational New Drug (IND) application for THE-349 soon.

Outlook: Despite challenges, Theseus remains committed to its mission of developing therapies that outsmart cancer resistance. With a focus on pan-variant kinase inhibitors, Theseus aims to bring forth innovative treatments that offer significant clinical benefits to cancer patients globally.

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. announces the successful completion of a tender offer by Concentra Biosciences, LLC, offering $4.05 per share in cash plus a contingent value right. The offer includes receiving 80% of net proceeds from certain programs and 50% of potential cost savings value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Concentra Biosciences, LLC and its subsidiary entered into a merger agreement with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) for a cash acquisition price of $3.90 to $4.05 per share, plus a non-tradeable contingent value right (CVR). The tender offer to acquire outstanding shares expires on February 13, 2024. 16,604,692 shares have been tendered, representing 37.2% of outstanding shares. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Theseus for a price per share of Theseus common stock of between $3.90 and $4.05 in cash, plus one non-tradeable contingent value right. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (THRX) received unsolicited acquisition proposals from Foresite Capital, LLC and OrbiMed Advisors LLC, as well as Tang Capital Partners, LP on behalf of Concentra Biosciences LLC. Foresite and OrbiMed intend to explore acquiring all outstanding shares in a going-private transaction, while Concentra Biosciences proposed to acquire all outstanding shares for $3.80 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
none
-
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) announced a strategic process to explore options for maximizing shareholder value, including a potential sale of assets, sale of the company, merger, or other strategic actions. The company also implemented a significant workforce reduction of approximately 72%, including the President of Research and Development. Theseus had cash, cash equivalents, and marketable securities of $225.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
none
-
Rhea-AI Summary
NASDAQ: THRX - Theseus Pharmaceuticals, Inc. to Participate in Fireside Chat at Stifel 2023 Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) reported business highlights and financial results for Q2 2023, including the advancement of lead candidate THE-349, a potential best-in-class fourth generation EGFR inhibitor. The company expects an IND submission for THE-349 in EGFR-mutant NSCLC in Q4 2023. Additionally, Theseus plans to nominate development candidates for BCR-ABL and next-generation KIT programs in H1 2024. The company also announced plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications. Theseus had $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
-
Rhea-AI Summary
Theseus Pharmaceuticals discontinues development of THE-630 in GIST, prioritizes THE-349 for EGFR mutant lung cancer. $234 million in cash as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags

FAQ

What is the market cap of Theseus Pharmaceuticals (THRX)?

The market cap of Theseus Pharmaceuticals (THRX) is approximately 181.3M.

What does Theseus Pharmaceuticals focus on?

Theseus Pharmaceuticals focuses on developing transformative targeted cancer therapies aimed at addressing treatment resistance through pan-variant tyrosine kinase inhibitors.

What is THE-349?

THE-349 is a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor designed to counteract C797X-mediated resistance in non-small cell lung cancer (NSCLC) patients treated with osimertinib.

Why was the THE-630 program discontinued?

The THE-630 program was discontinued due to dose-limiting toxicities observed in clinical trials, which exceeded the maximum tolerated dose.

What recent financial milestone did Theseus achieve?

As of June 30, 2023, Theseus had raised $234.2 million in cash and equivalents, expected to fund operations through 2026.

What is the significance of the merger with Concentra Biosciences?

The merger with Concentra Biosciences is aimed at maximizing shareholder value, with Concentra acquiring Theseus for a price per share between $3.90 and $4.05, plus contingent value rights.

What are Theseus' plans for its BCR-ABL and KIT programs?

Theseus plans to nominate development candidates for its next-generation BCR-ABL and KIT programs in early 2024.

How does Theseus aim to outsmart cancer resistance?

Theseus develops pan-variant kinase inhibitors to target all classes of cancer-causing and resistance mutations, thereby addressing the challenge of treatment resistance.

What other candidates are in Theseus' pipeline?

In addition to THE-349, Theseus is developing a pan-variant BCR-ABL inhibitor for CML and Ph+ ALL, and a highly selective, pan-variant KIT inhibitor for early-line GIST.

What are pan-variant tyrosine kinase inhibitors?

Pan-variant tyrosine kinase inhibitors are therapies designed to target multiple variants of cancer-causing and resistance mutations within specific proteins, offering a comprehensive approach to treatment.

Where can I find more information about Theseus Pharmaceuticals?

For more information, visit the company's website at www.theseusrx.com.

Theseus Pharmaceuticals, Inc.

Nasdaq:THRX

THRX Rankings

THRX Stock Data

181.28M
20.05M
2.56%
84.08%
0.9%
Biotechnology
Healthcare
Link
United States
Cambridge